Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Inc. announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.
Crazy Questions and Maple Madness: Shannon Gervais Faces Brain Smarts
Hold onto your stethoscopes, because Vet Candy’s Brain Smarts is back with an episode that’s equal parts trivia, chaos, and Canadian charm. This time, veterinary superstar Shannon Gervais is taking the hot seat—and she’s not just answering questions, she’s opening her very own vet clinic in Alberta, Canada- Nova Vet. Yep, she’s bringing her skills, smarts, and a little Maple Madness to the Great White North.
Zoetis : Acquires Veterinary Pathology Group to Strengthen Veterinary Diagnostics in UK and Ireland
Zoetis Inc. today announced the acquisition of Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with multiple locations across the UK and Ireland. The acquisition further expands Zoetis' comprehensive diagnostics portfolio and reinforces its commitment to advancing animal health through innovative, high-quality diagnostic solutions.
Zoetis announced the launch of Vanguard Recombishield
Zoetis announced the U.S. launch of Vanguard® Recombishield™ (Bordetella bronchiseptica vaccine), a new injectable vaccine to protect against Bordetella bronchiseptica, also known as kennel cough. Licensed by the U.S. Department of Agriculture (USDA) on March 4, 2025, Recombishield is the first and only vaccine for dogs with pertactin protein for an optimized immune response. This innovation in Bordetella protection uses recombinant technology to provide a comfortable immunization experience for the pet, with minimal pain, swelling, stinging and sensitivity.
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats.
SARS-CoV-2 Vaccination in Non-Domestic Species: Insights from the Toronto Zoo
The SARS-CoV-2 pandemic has highlighted the virus’s broad host range, including susceptibility in non-domestic mammals housed in zoological collections. Vaccination has been recommended for susceptible species, particularly to protect endangered populations, but data regarding vaccine safety and efficacy in exotic animals have been scarce.